19
Aug
2016

Illumina Takeout? Ha!, Portola Stumbles, and NYT Biotech Ace Moves On

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

RevMed’s Moment in the Sun, In Vivo CAR-Ts Shine & NewLimit’s Healthspan Haul
Vaccines Get a Boost, Apogee Hunts Down Dupixent, GSK Raises the Bar in HepB
Lilly’s Triple-G Delivers, Parabilis Eyes IPO, & Regeneron’s LAG-3 Whiff
FDA Boss Pushed Out, BMS Bets on China & Isomorphic’s Megaround